Background {#Sec1}
==========

IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and accounts for 45% of primary glomerular disease in China, significantly contributing to the global burden of chronic kidney disease (CKD) \[[@CR1], [@CR2]\]. Patients with IgAN are often diagnosed at a young age, and about 30% of the patients develop end-stage renal disease (ESRD) in 10--20 years \[[@CR1], [@CR3]\]. Proteinuria, decreased kidney function, and hypertension at diagnosis are the independent risk factors for progression to ESRD. Among them, persistent proteinuria is the strongest predictor for developing ESRD \[[@CR4]--[@CR6]\]. According to the 2016 Oxford Classification of IgAN, mesangial or endocapillary hypercellularity, crescents, segmental glomerulosclerosis, and tubular atrophy/interstitial fibrosis are pathological indicators of poor renal outcome \[[@CR7]\].

The Latest Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis recommends angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) with uptitration to achieve a maximally tolerated dose as an initial therapy for progressive IgAN. For those patients with persistent proteinuria \> 1 g per day and estimated glomerular filtration rate (eGFR) \> 50 mL/min/1.73 m^2^, a 6-month course of high-dose corticosteroid therapy is suggested despite 3--6 months of optimized supportive care (ACEI, ARB, or both, and blood-pressure control). Intensive immunosuppression (corticosteroid with cyclophosphamide (CTX) or azathioprine) is reserved for patients with crescents in more than half of the glomeruli and rapidly deteriorating renal function \[[@CR8]\]. A meta-analysis has shown that IgAN patients with more serious pathological features may be more resistant to steroid therapy than other IgAN patients according to the Oxford classification system \[[@CR9]\].

However, the benefits of systemic immunosuppression have been questioned in recently completed trials. Conflicting results indicate the presence of severe adverse events (SAEs), which imply long-term immunosuppression must be balanced against benefits carefully \[[@CR10]--[@CR12]\]. Other general immunosuppressants are waiting for more high-quality trials to assess their safety and efficacy, including mycophenolate mofetil \[[@CR13], [@CR14]\], calcineurin inhibitors \[[@CR15]\], and targeted immunosuppression regimens, like rituximab \[[@CR16]\], targeted release formation budesonide \[[@CR17]\], and the selective enzyme spleen tyrosine kinase inhibitor fostamatinib, which was studied in a recently completed phase II randomized controlled trial (RCT; ClinicalTrials.gov, NCT02112838),. Above all, for high-risk IgAN, safe, disease-specific therapy remains limited.

Chinese medicine is gradually accumulating evidence-based applications in CKD and has been widely approved for its positive role in prevention and treatment of IgAN \[[@CR18]--[@CR21]\]. Yi-Qi-Qing-Jie formula (YQF) was developed from the classical Chinese prescription Yupingfeng San, Yinqiao San, and Wuweixiaodu Yin, the main constituents including *Astragali radix* (HUANG QI), *atractylodes rhizome* (BAI ZHU), *Radix Saposhnikoviae* (FANG FENG), *oldenlandia diffusa* (BAI HUA SHE SHE CAO), *Rhizoma Dioscoreae Nipponicae* (CHUAN SHAN LONG), and *raw rhubarb* (DA HUANG). We conducted an ambispective cohort study \[[@CR22]\] that matched 34 high-risk IgAN patients (UTP \> 3 g/24 h and eGFR \< 60 ml/min/1.73 m^2^) who received YQF combined therapy (treatment group) to 34 patients who received immunosuppression monotherapy (control group) from the Peking University First Hospital nephrology department, on the basis of renin-angiotensin system blockade (RASB). This YQF combined therapy exhibited a potential renal protective effect during the mean follow-up period of 43 months. Five patients (14.71%) developed ESRD (Fig. [1](#Fig1){ref-type="fig"}) and no SAEs were associated with the immunosuppressants. In a study by Mitsuiki et al. \[[@CR23]\], which was similar to our treatment protocol, six patients (22%) treated with prednisolone and cyclophosphamide reached ESRD during the mean follow-up period of 66.5 months, and two patients (7.4%) suffered adverse effects of immunosuppression during treatment. However, their study did not use a standardized clinical design. Hence, we will conduct a randomized, prospective, double-blind (placebo) controlled trial to confirm that, compared with immunosuppressive therapy alone, YQF combined with immunosuppressive therapy will be superior with regard to renal function protection and reducing severe treatment-related adverse effects in patients with high-risk IgA nephropathy. Fig. 1Cumulative renal survival curves

Methods/design {#Sec2}
==============

Study design {#Sec3}
------------

This is a single-center, prospective, double-blind, placebo-controlled randomized trial. This clinical trial is reported according to the Standard Protocol Interventions: Recommendations for Interventional Trials (SPIRIT) guidelines \[[@CR24]\] (the study schedule (SPIRIT figure) is outlined in Fig. [2](#Fig2){ref-type="fig"}, and the checklist is provided in Additional file [1](#MOESM1){ref-type="media"}). Fig. 2Study schedule (SPIRIT figure). \* End stage kidney disease requiring ongoing maintenance dialysis or renal transplantation. \*\* Death due to kidney disease

Setting and participants {#Sec4}
------------------------

Sixty high-risk IgAN participants will be followed up until 50% (30 of them) have a composite endpoint or have been followed for 3 years. The trial will be conducted at Guang'anmen Hospital, Beijing, China, and was approved by the Ethics Committee of Guang'anmen Hospital (approval number 2018--055-KY-01) in accordance with the Declaration of Helsinki and the principles outlined in the "Guidelines for Good Clinical Practice" from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Tripartite Guideline (January 1997). Recruited participants will be self-selected or referred from inpatients or outpatients and hospital-based WeChat advertisements. Potential participants will be pre-screened through WeChat, further assessed by our investigator, and given consent to participate in the study. Participation will be voluntarily and all subjects will sign informed consent.

Objectives {#Sec5}
----------

Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of severe treatment-related adverse events of YQF combined therapy compared with immunosuppression monotherapy in high-risk IgAN.

Rationale of high-risk IgAN {#Sec6}
---------------------------

Several high-quality clinical trials \[[@CR11], [@CR12]\] have interpreted the concept of "high-risk" clinically and pathologically while not specifically. Following the inclusion criteria of these trials, this study will define "high-risk" as persistent heavy proteinuria (≥ 1 g/d despite intensive optimal supportive care) with impaired renal function (eGFR 15--60 ml/min/1.73 m^2^).

Inclusion and exclusion criteria {#Sec7}
--------------------------------

The inclusion criteria are as follows: (1) in accordance with IgAN pathological diagnosis, renal biopsy within 6 months; (2) persistent proteinuria ≥ 1 g/d despite at least 8 weeks of optimal supportive care (maximally tolerated RAS blocker which refers to no symptomatic hypotension, no hyperkalemia, and serum creatinine (SCr) increased by not more than 30% of baseline, blood pressure control meeting targets (135/85 mmHg or lower), and dietary management (sodium intake less than 6 g/d, protein intake of 0.6--0.8 g/kg/day, and low-fat diet)); (3) eGFR 15 to 60 ml/min/1.73 m^2^, calculated with the use of CKD-EPI Creatinine Equation 2009; (4) patients who maintain regular follow-up at Guang'anmen Hospital, agree to participate, and provide informed consent (Additional file [2](#MOESM2){ref-type="media"} shows the informed consent form in more detail).

The exclusion criteria are as follows: (1) secondary IgAN; (2) comorbidity of other primary or secondary glomerular diseases; (3) comorbidity of severe primary diseases such as cardiovascular, hepatic, cerebral, and hematopoietic system diseases or mental disorders; (4) allergy or intolerance to the experimental medication (e.g., RAS blockers, prednisolone, cyclophosphamide, YQF compound and its placebo compound); (5) contraindications to immunosuppression therapy---acute and chronic infectious diseases, malignancies, leukopenia, thrombocytopenia, gastrointestinal hemorrhage, ulcers of stomach or duodenum, post-transplantation; (6) pregnant or lactating women; (7) unwilling to participate in this study, failure to accept or tolerate Chinese medicine compound; (8) history of alcohol or drug abuse; (9) poor compliance, loss to follow-up; (10) participation in another clinical investigation.

Randomization and masking {#Sec8}
-------------------------

Subjects that are eligible to participate and have signed the informed consent will be randomly selected in 1:1 ratio after the run-in phase such that the YQF group and the control group will both include 30 patients. A central stochastic system developed by the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, based on SAS 9.4.3 (SAS Institute, Cary, NC, USA), will be used to perform the randomization. Independent experts will generate the randomization sequence, which will be concealed in opaque, sealed, and stapled envelopes. Participants, investigators, and all other members with clinical involvement in the trial will be blinded to the treatment assignment for the duration of the trial. Relevant personnel have clear divisions of labor and strict permission restrictions. The blinding will be removed only if a participant has severe side effects that the affected participant will be withdrawn.

Interventions {#Sec9}
-------------

### Run-in period (pre-trial, 4 weeks) {#Sec10}

Eligible participants will enter a run-in period for 4 weeks, during which they will receive an optimized basic treatment, including lifestyle management (smoking cessation, alcohol restriction, weight control, low-salt and proper protein diet), maximum tolerated dose of ACEI or ARB, blood pressure control to a target below 135/85 mmHg, control of glycated hemoglobin ≤ 7% using insulin or oral hypoglycemic agents in diabetics, reaching targets in serum uric acid (UA) (\< 420 μmol/L in male, \< 360 μmol/L in female) by UA-lowering medications in hyperuricemia, and stopping other Chinese medicine treatments.

### Treatment period (in-trial, 48 weeks) {#Sec11}

At the end of the run-in period, participants who fulfill all eligibility criteria and no exclusion criteria will be randomized to either the YQF combined immunosuppression therapy (YQF group) or matching placebo combined with immunosuppression therapy (control group) in a double-blind fashion with a total treatment period of 48 weeks. Both groups will continue their basic pre-trial treatment.

#### Immunosuppression therapy {#FPar1}

Immunosuppression therapy comprises oral prednisolone (0.5--0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5--10 mg/day every 4 weeks, with a total treatment period of 24--32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8--1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 10^9^/L and platelets \< 50.0 × 10^9^/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.

#### Yi-Qi-Qing-Jie formula {#FPar2}

YQF is obtained from Sichuan Xinlvyao Co. (Chengdu, Sichuan, China), which uses a manufacturing process complying with Chinese GMP. The compounds are blends of individual herbal extracts from YQF (consisting of *Astragalus membranaceus*, *Saposhnikovia divaricata* (*turcz.*) *Schischk*, *Flos lonicerae*, *Angelica sinensis*, *Dioscorea nipponica*, *Hedyotis diffusa Willd*, *rhubarb*, *Spatholobus suberectus*) dissolved in 150 ml boiled water and taken orally twice a day.

#### YQF placebo {#FPar3}

The YQF placebo is obtained from Sichuan Xinlvyao Co. (Chengdu, Sichuan, China), which uses a manufacturing process complying with Chinese GMP. The major component of the placebo is malt dextrin and it comes in packaging with a similar appearance to YQF; it is also dissolved in 150 ml boiled water and taken orally twice a day.

### Follow-up period (post-trial) {#Sec12}

All participants will continue their previous basic treatments.

### Follow-up assessments {#Sec13}

Participants will be visited at regular intervals for a planned mean of at least 3 years until the end point occurs. In the run-in and treatment periods, study visits occur every 4 weeks until week 24**,** and every 12 weeks face-to-face or by telephone according to the choice of the participants and investigators until the end of the trial. Measurements will be performed at qualified laboratories during the follow-up period.

Laboratory measurements include: (1) urine tests---24 h urine total protein (UTP) measured using biuret method and albumin/creatinine ratio (ACR); (2) blood tests---serum creatinine, albumin (ALB), blood urea nitrogen (BUN), UA, blood glucose (GLU), total cholesterol (CHO), electrolytes (K, Na, Cl), triglyceride (TG), alanine transaminase (ALT), aspartate aminotransferase (AST), hemoglobin (HGB), white blood cell count (WBC), and platelets (PLT).

Body weight, appetite, excretory functions, stamina, mobility, sleep, etc. will also be monitored. Vital sign monitoring includes temperature, respiration, pulse, and blood pressure. Subjective symptoms and chronic inflammation status will be recorded by investigators on case report forms (CRFs) as syndrome scores for effectiveness assessment. Each symptom is scored on a four-point scale ranging from 0 (absent) to 3 (severe), and a total symptom score is calculated by adding together the values for all three symptoms. Similarly, we get a total chronic inflammation status score (Additional file [5](#MOESM5){ref-type="media"}).

The final follow-up duration will be continued until the occurrence of the primary end point or 3 years (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Clinical trial flow diagram

### Outcome measures definition {#Sec14}

The primary composite end point is defined as the first occurrence of 40% decrease in eGFR from baseline eGFR, progression to continuous renal replacement, or death due to renal disease.

The secondary composite end points are defined as: (1) main outcome measurement---the mean annual reduction in eGFR based on SCr (eGFR slope); (2) proteinuria remission (prescribed as proteinuria \< 0.5 g/day) at weeks 24, 36, and 48 in the treatment period, and months 6, 12, 24, or 36 if possible. The remission rate of symptoms and inflammation status will be evaluated at week 48.

### Adverse events and safety {#Sec15}

Adverse events and SAEs will be inspected at each follow-up, including infections requiring hospitalization, thromboembolic events, hepatic dysfunction, hematopoietic disorders, fracture or osteonecrosis, and new onset diabetes. SAEs are defined according to the definitions of Good Clinical Practice (GCP) by the China Food and Drug Administration (CFDA). The researcher will report the events to the principal investigator and the ethics committee within 24 h of occurrence of the SAE, who will give a final decision on whether or not to continue the study treatment and identify appropriate support for the patients involved. Furthermore, treatment interruption due to any events and relevant measures will be recorded on the CRFs. The influence of all adverse events will be analyzed at the end of the trial.

### Termination and withdrawal {#Sec16}

Participants will be withdrawn from the trial in any of the following situations: (1) SAEs related to immunosuppression---severe infections (e.g., pulmonary infection requiring ventilatory support), serious granulocytopenia/thrombocytopenia (e.g., WBC \< 2.0 × 10^9^/L, PLT \< 20 × 10^9^/L); (2) participants or investigators fail to obey the study protocol; (3) poor compliance where less than 30% of experimental medications are taken; (4) termination requested by data and safety monitoring board, ethics committee, or study principal investigator---in the best interest of the participants, the investigator can request for termination of individual participants if the study treatment is of insignificant clinical benefit.

### Sample size calculation {#Sec17}

On the basis of our recent trial \[[@CR22]\], where eGFR slope after 12 months of treatment was the primary endpoint, we define δ = (μ1 − μ2)/σ, where σ is the pooled standard deviation (for sample size calculation, see Additional file [4](#MOESM4){ref-type="media"}) and μ is the treated mean. We calculate δ = 0.994, approximately equivalent to 1.0, according to the look-up table of counts (Medical Statistics Method, PH Jin, Shanghai Medical College Press; Additional file [3](#MOESM3){ref-type="media"}), and using α = 0.05 and β = 0.1, we require a sample size of 46 participants. Assuming 25% dropout and in view of *n* = 30 as a rule of thumb for a small size clinical trial, we plan to recruit 60 patients for this study (30 patients per group).

Statistical analysis {#Sec18}
--------------------

Investigators will fill out the CRFs when making follow-up observations by interviewing the participants. Paper CRFs will be entered into a database by those investigators in order to ensure data validity. An independent statistician will unblind and extract clean data from the final database for analysis after locking. Data analysis of treatment effect and safety follows the intention-to-treat principle. Investigators can access the final database only when both the data analysis and study are complete. The endpoint events will be described by Kaplan--Meier method and the between-group difference will be compared using log-rank test. *t*-Test will be used for scale variables, chi-square test or variance analysis will be used for binomial and nominal variables, and nonparametric test will be used for ordinal variables. The eGFR slope will be calculated as the individual slopes obtained from individual linear regressions of eGFR during the follow-up period. All analyses will be performed using SPSS software version 23.0 (IBM Analytics). Differences are considered to be statistically significant for two-sided *P* \< 0.05.

### Quality control and monitoring {#Sec19}

A Data and Safety Monitoring Board (DSMB) will be established to monitor the performance of the overall study, ensure the safety and welfare of participants, and review quality of the data through regular meetings. The DSMB, which is independent of the present trial, consists of three members, including a clinical nephrologist, a statistician, and an ethics specialist (Additional file [6](#MOESM6){ref-type="media"}). It will assess whether participants receive good clinical care and safety concerns are interpreted and addressed appropriately. Moreover, the DSMB will make recommendations and decisions on any modification of the protocol, even termination of the study based on the interim analysis of efficacy and safety. In order to improve compliance with the protocol until completion, we will intensify patient management through one-to-one WeChat follow-up by designated researchers. Participants' medical records (including CRFs, consent forms, etc.) will be archived securely and used only within the validity period.

Intention-to-treat analysis will be used for subjects who drop out or withdraw from the study, which includes every subject who is randomized according to randomized treatment assignment regardless of whether he/she receives the treatment or not; they will be included in the assigned group for statistical analysis of efficacy.

Last observation carried forward method will be applied in cases of missing data of longitudinal observations.

Discussion {#Sec20}
==========

As IgAN is considered to be an autoimmune disease, it is logical that immunosuppression therapy may be effective \[[@CR10], [@CR25]\]; as the therapeutic benefits of intensive supportive care show, it is the cornerstone of treatment in IgAN. Recently completed high-profile RCTs with rigorous standardization and optimization of supportive management have focused on the outcomes of additional immunosuppression. The STOP-IgAN trial \[[@CR11]\] showed that additional immunosuppression therapy (oral corticosteroids plus CTX and azathioprine) did not provide substantial renal protection for those with eGFR 30--59 ml/min/1.73 m^2^; this population included one death due to sepsis related to steroids. However, the trial excluded patients with 24 h UTP \> 3.5 g, eGFR \< 30 ml/min/1.73 m^2^, or in whom eGFR decreased more than 30% at the end of the 6-month run-in phase, which often underlies a relatively high risk for disease progression and a better response to steroids. The TESTING study \[[@CR12]\], after a 3-month run-in phase of optimal supportive treatment, recruiting participants with 24 h UTP \> 1 g and eGFR of 20--120 ml/min/1.73 m^2^, was terminated because of two deaths from infection and excess SAEs in the methylprednisolone group. Early results could not demonstrate definite treatment efficacy for steroid therapy, though they did indicate short-term potential renal benefits. Both trials highlight the safety concerns about immunosuppression and the need to seek an alternative approach which is safe and effective in high-risk IgAN.

Traditional Chinese medicine has shown promising effects regarding safety and renoprotection in some RCTs on chronic kidney diseases, for instance, *Abelmoschus manihot* \[[@CR26]\], although it is notable that this trial excluded patients with impaired renal function (eGFR \< 60 ml/min/1.73 m^2^) and nephrotic syndrome. In clinical practice, we also get patient feedback about symptomatic amelioration with respect to the application of Chinese medicine. Therefore, we are conducting TCM-WINE, a prospective, double-blind, single-placebo-controlled, randomized trial aiming to evaluate the safety and long-term outcomes with YQF herbal compound compared to immunosuppression monotherapy in treating high-risk IgAN. The results of TCM-WINE will provide clinical evidence for the efficacy and safety of YQF compound. Moreover, this trial will serve as an important step toward a new era of treatment for high-risk IgAN.

Trial status {#Sec21}
============

Recruitment for this study began on 4 July 2019 (protocol version 03, 22 November 2019). It is estimated that recruitment will be completed in August 2020.
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ACEI

:   Angiotensin-converting enzyme inhibitor

ACR

:   Albumin/creatinine ratio

ALB

:   Albumin

ALT

:   Alanine transaminase

ARB

:   Angiotensin-receptor blocker

AST

:   Aspartate aminotransferase

BUN

:   Blood urea nitrogen

CFDA

:   China Food and Drug Administration

CHO

:   Total cholesterol

CKD

:   Chronic kidney disease

CRF

:   Case record form

CTX

:   Cyclophosphamide

DSMB

:   Data and Safety Monitoring Board

eGFR

:   Estimated glomerular filtration rate

ESRD

:   End-stage renal disease

GCP

:   Good Clinical Practice

GLU

:   Blood glucose

HGB

:   Hemoglobin

IgAN

:   Immunoglobulin A nephropathy

KDIGO

:   Kidney Disease: Improving Global Outcomes

PLT

:   Platelets

RASB

:   Renin-angiotensin system blockade

RCT

:   Randomized controlled trial

SAE

:   Severe adverse event

SCr

:   Serum creatinine

SPIRIT

:   Standard Protocol Interventions: Recommendations for Interventional Trials

TG

:   Triglyceride

UA

:   Uric acid

UTP

:   Urine total protein

WBC

:   White blood cell count

YQF

:   Yi-Qi-Qing-Jie formula granule
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